Alembic Pharmaceuticals’ arm gets nod for Investigational New Drug application

02 Dec 2020 Evaluate

Alembic Pharmaceuticals’ step down wholly owned subsidiary -- Rhizen has received approval from US Food and Drug Administration (USFDA) for its Investigational New Drug (IND) application to study its oral DHODH inhibitor for SARS-CoV-2 infection. The initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020.

Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid19 viral replication.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

939.85 9.85 (1.06%)
19-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1525.00
Dr. Reddys Lab 5942.65
Cipla 1345.35
Zydus Lifesciences 925.95
Lupin 1547.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.